Janux Therapeutics Reports Q2 2026 Financial Results (8-K)

What Happened Janux Therapeutics, Inc. announced on August 6, 2026 that it issued a press release reporting its financial results for the three and six months ended June 30, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K (Item 2.02), and the filing states the furnished information is not “filed” for purposes of Section 18 of the Exchange Act.

Key Details

• Filing date: August 6, 2026 (Form 8-K).
• Reporting periods: three and six months ended June 30, 2026.
• Exhibit included: Exhibit 99.1 — press release announcing the results.
• Furnished (not filed) disclosure; signed by President & CEO David Campbell, Ph.D.

Why It Matters This 8-K informs investors that Janux has published its quarterly and year-to-date financial results; the attached press release contains the specific earnings, revenue, expense and cash-related figures investors will want to review. Because the release is furnished (not “filed”), investors should consult the press release itself and upcoming periodic reports (e.g., Form 10-Q) for complete financial details and formal disclosures.